UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 22, 2003
PROTEIN DESIGN
LABS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-19756 |
|
94-3023969 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
34801 Campus Drive |
||||
|
Fremont, California 94555 |
||||
|
(Address of principal executive offices) |
|
(Zip Code) |
||
|
|
||||
|
Registrant’s telephone number, including area code: (510) 574-1400 |
||||
|
|
||||
|
Not Applicable |
||||
|
(Former name or former address, if changed since last report) |
||||
Item 5. Other Events
On December 22, 2003, Protein Design Labs, Inc. (“PDL”) issued a press release announcing that PDL and Genentech concluded a definitive agreement which resolves their dispute relating to PDL’s antibody humanization patents and certain of Genentech’s humanized antibodies. A copy of PDL’s press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 7. Financial Statements and Exhibits
|
(c) Exhibits |
|
|
|
|
|
|
|
99.1 |
|
Press Release dated December 22, 2003. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PROTEIN DESIGN LABS, INC. |
|
|
|
|
|
|
|
|
|
|
Date: December 24, 2003 |
|
|
|
|
|
|
|
|
By: |
/s/ Sergio Garcia-Rodriguez |
|
|
|
Sergio Garcia-Rodriguez |
|
|
|
Vice
President, Legal,General Counsel and |
EXHIBIT INDEX
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated December 22, 2003. |